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Abstract: This overview of the 4th edition of the World Health 
Organization (WHO) Classification of thymic tumors has two aims. 
First, to comprehensively list the established and new tumor enti-
ties and variants that are described in the new WHO Classification 
of thymic epithelial tumors, germ cell tumors, lymphomas, dendritic 
cell and myeloid neoplasms, and soft-tissue tumors of the thymus 
and mediastinum; second, to highlight major differences in the new 
WHO Classification that result from the progress that has been made 
since the 3rd edition in 2004 at immunohistochemical, genetic and 
conceptual levels. Refined diagnostic criteria for type A, AB, B1–B3 
thymomas and thymic squamous cell carcinoma are given, and it is 
hoped that these criteria will improve the reproducibility of the clas-
sification and its clinical relevance. The clinical perspective of the 
classification has been strengthened by involving experts from radi-
ology, thoracic surgery, and oncology; by incorporating state-of-the-
art positron emission tomography/computed tomography images; 
and by depicting prototypic cytological specimens. This makes 
the thymus section of the new WHO Classification of Tumours of 
the Lung, Pleura, Thymus and Heart a valuable tool for patholo-
gists, cytologists, and clinicians alike. The impact of the new WHO 
Classification on therapeutic decisions is exemplified in this over-
view for thymic epithelial tumors and mediastinal lymphomas, and 
future perspectives and challenges are discussed.
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The 4th edition of the World Health Organization (WHO) Classification of Tumours of the Lung, Pleura, Thymus 
and Heart is largely a revision of the 3rd edition that was pub-
lished in 2004 under the editorship of Travis et al.1 It was for 
the first time that the WHO Classification gathered all thoracic 
tumors in one book. In contrast, the previous 2nd edition of the 
WHO Classification of Tumours of the Thymus, edited by Dr. 
Juan Rosai, was published in 1999 and addressed only thymic 
tumors. In this edition, the concept of type A, AB, and B1–B3 
nomenclature was introduced for thymomas.2 The 3rd and the 
new 4th editions3 perpetuate this unique nomenclature for thy-
momas because it has achieved worldwide acceptance and has 
not been challenged seriously by new data.4 In the 3rd edition, 
the histopathology of thymic tumors was complemented with 
descriptions of their clinical symptoms, macroscopic, immu-
nohistological and genetic features, and prognostic data.
In the 4th edition of the WHO Classification of thoracic 
tumors edited by William D. Travis, Elizabeth Brambilla, 
Allen Burke, Alexander Marx, and Andrew G. Nicholson, 
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this interdisciplinary perspective on thymic tumors is further 
strengthened by involving clinical experts from radiology, tho-
racic surgery, and oncology as co-authors and by the incorpo-
ration of state-of-the-art computed tomography and positron 
emission tomography/computed tomography images (Fig. 1) 
and cytology (Fig. 2). The foundations for this interdisciplin-
ary approach and the broad consensus on conceptual changes 
and histological criteria for improved thymoma subtyping 
were greatly aided by two international interdisciplinary con-
ferences organized by the International Thymic Malignancy 
Interest Group (ITMIG) in New York City and Mannheim, 
Germany and convened experts from North America, Asia, 
and Europe. Another focus of the 4th edition was the revi-
sion and refinement of histological and immunohistochemical 
diagnostic criteria for a more robust and reproducible subtyp-
ing of thymomas and for the distinction between thymomas 
and thymic carcinomas. The necessary preparatory work for 
this refinement of histological criteria was achieved at the 
ITMIG consensus meetings in New York and Mannheim5 and 
is reflected in the 4th edition not only in the “histopathology” 
but also “differential diagnosis” paragraphs. Furthermore, the 
epidemiological and prognostic data in the chapters on thy-
mic epithelial tumors (TETs) were for the first time not only 
based on single-center experience or small meta-analysis, but 
on recent data derived from the worldwide, retrospective data-
base of the ITMIG that has compiled more than 6000 cases 
of thymomas, thymic carcinomas, and thymic neuroendocrine 
neoplasms.6–9
In the chapters on germ cell tumors (GCTs), lymphoid, 
hematopoietic and soft-tissue neoplasms, there are no changes 
of concept or diagnostic criteria in the 4th compared with 
the 3rd edition. Minor revisions concern new immunohisto-
chemical and genetic data and the adaptation of nomencla-
ture and definitions to the WHO Classifications of Tumours of 
the Haematopoietic and Lymphoid Tissue,10 Tumours of Soft 
Tissues and Bone11 and Tumours of the Urinary System and 
Male Genital Organs (H. Moch, et al., forthcoming).
The following “overview” focuses on differences 
between the 3rd and 4th edition of the WHO Classification 
of tumors of the thymus rather than providing comprehensive 
description of the tumors.
NOVELTIES IN THE NEW WHO CLASSIFICATION 
OF MEDIASTINAL TUMORS
Thymomas
Conceptual continuity
The nomenclature of the major thymoma subtypes based 
on letters and numbers (type A, AB, B1–B3)2 is maintained in the 
4th edition (Table 1), as is the recommendation to use the modi-
fied Masaoka–Koga system for the staging of thymomas.12 A 
new tumor, node, metastasis (TNM) staging system is currently 
being jointly developed by the International Association for 
the Study of Lung Cancer and ITMIG, but preliminary staging 
FIGURE 1.  Images of a fluorodeoxyglucose (FDG) positron 
emission tomography–computed tomography (PET-CT) of 
a 71-year-old woman with type B3 thymoma. A, Axial CT 
image at the level of the left main bronchus (B) demonstrates 
an anterior mediastinal mass (M) and low right paratra-
cheal lymphadenopathy. Infiltration of superior recess of the 
pericardium is indicated by arrow. B. Axial fused image at the 
same level demonstrates that both the primary tumor and 
the metastasis are FDG avid.
FIGURE 2.  Cytology of World Health Organization (WHO) 
type B2 thymoma (fine needle aspirate). Large tumor cells 
with elongated or round nuclei and nucleoli intermingled 
with small lymphocytes.
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TABLE 1.  Epithelial Tumors
Thymoma
  Type A thymoma, including atypical variant 8581/3a
  Type AB thymoma 8582/3a
  Type B1 thymoma 8583/3a
  Type B2 thymoma 8584/3a
  Type B3 thymoma 8585/3a
  Micronodular thymoma with lymphoid stroma 8580/1a
  Metaplastic thymoma 8580/3
  Other rare thymomas
   Microscopic thymoma 8580/0
   Sclerosing thymoma 8580/3
   Lipofibroadenoma 9010/0a
Thymic carcinoma
  Squamous cell carcinoma 8070/3
  Basaloid carcinoma 8123/3
  Mucoepidermoid carcinoma 8430/3
  Lymphoepithelioma-like carcinoma 8082/3
  Clear cell carcinoma 8310/3
  Sarcomatoid carcinoma 8033/3
  Adenocarcinomas
   Papillary adenocarcinoma 8260/3
   Thymic carcinoma with adenoid cystic  
   carcinoma-like features
8200/3a
   Mucinous adenocarcinoma 8480/3
   Adenocarcinoma, NOS 8140/3
  NUT carcinoma 8023/3a
  Undifferentiated carcinoma 8020/3
  Other rare thymic carcinomas
   Adenosquamous carcinoma 8560/3
   Hepatoid carcinoma 8576/3
   Thymic carcinoma, NOS 8586/3
Thymic neuroendocrine tumors
  Carcinoid tumors
   Typical carcinoid 8240/3
   Atypical carcinoid 8249/3
  Large-cell neuroendocrine carcinoma 8013/3
   Combined large-cell neuroendocrine carcinoma 8013/3
  Small-cell carcinoma (SCC) 8041/3
   Combined SCC 8045/3
Combined thymic carcinomas
Germ cell tumors of the mediastinum
  Seminoma 9061/3
  Embryonal carcinoma 9070/3
  Yolk sac tumor 9071/3
  Choriocarcinoma 9100/3
  Teratoma
   Teratoma, mature 9080/0
   Teratoma, immature 9080/1
  Mixed germ cell tumors 9085/3
  Germ cell tumors with somatic-type solid malignancy 9084/3
  Germ cell tumors with associated hematological malignancy 9086/3a
Lymphomas of the mediastinum
  Primary mediastinal large B-cell lymphoma 9679/3
  Extranodal marginal zone lymphoma of mucosa-associated 
lymphoid tissue (MALT lymphoma)
9699/3
(Continued )
  Other mature B-cell lymphomasb
  T lymphoblastic leukaemia / lymphoma 9837/3
  Anaplastic large-cell lymphoma (ALCL) and other
 rare mature T- and NK-cell lymphomas
   ALCL, ALK-positive (ALK+) 9714/3
   ALCL, ALK-negative (ALK-) 9702/3
  Hodgkin lymphoma 9650/3
  B-cell lymphoma, unclassifiable, with features intermediate 
between diffuse large B-cell and classical Hodgkin lymphoma
9596/3
Histiocytic and dendritic cell neoplasms of the mediastinum
  Langerhans cell lesions
   Thymic Langerhans cell histocytosis 9751/1
   Langerhans cell sarcoma 9756/3
  Histiocytic sarcoma 9755/3
  Follicular dendritic cell sarcoma 9758/3
  Interdigitating dendritic cell sarcoma 9757/3
  Fibroblastic reticular cell tumor 9759/3
  Indeterminate dendritic cell tumor 9757/3
Myeloid sarcoma and extramedullary acute myeloid leukaemia 9930/3
Soft-tissue tumors of the mediastinum
  Thymolipoma 8850/0
  Lipoma 8850/0
  Liposarcoma
   Well-differentiated 8850/3
   Dedifferentiated 8858/3
   Myxoid 8852/3
   Pleomorphic 8854/3
  Solitary fibrous tumor 8815/1
   Malignant 8815/3
  Synovial sarcoma
   Synovial sarcoma, NOS 9040/3
   Synovial sarcoma, spindle cell 9041/3
   Synovial sarcoma, epithelioid cell 9042/3
   Synovial sarcoma, biphasic 9043/3
  Vascular neoplasms
   Lymphangioma 9170/0
   Hemangioma 9120/0
   Epithelioid hemangioendothelioma 9133/3
   Angiosarcoma 9120/3
  Neurogenic tumors
   Tumors of peripheral nerves
   Ganglioneuroma 9490/0
   Ganglioneuroblastoma 9490/3
   Neuroblastoma 9500/3
Ectopic tumors of the thymus
  Ectopic thyroid tumors
  Ectopic parathyroid tumors
  Other rare ectopic tumors
The morphology codes are from the International Classification of Diseases 
for Oncology (ICD-O). Behavior is coded /0 for benign tumors; /1 for unspecified, 
borderline, or uncertain behavior; /2 for carcinoma in situ and grade III intraepithelial 
neoplasia; and /3 for malignant tumors. The classification is modified from the previous 
WHO classification,1 taking into account changes in our understanding of these lesions.
aThese new codes were approved by the IARC/WHO Committee for ICD-0.
bThis can be any mature B-cell lymphoma and the respective ICD-O code from the 
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.10
WHO, World Health Organization; NUT, nuclear protein in testis.
TABLE 1.  (Continued    )
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proposals13,14 should not be used in clinical settings before the 
approval by the Union for International Cancer Control (UICC) 
and the American Joint Committee on Cancer (AJCC).15
Conceptual changes
One new feature of the 4th edition is that some histo-
logical criteria for the characterization of thymomas using 
hematoxylin and eosin (HE)-stained specimens are now con-
sidered “obligatory/indispensable,” and others as “optional” 
according to their importance for diagnosis (Table 2).5 It is 
hoped that these clarifications will reduce previous ambiguity 
and may help to overcome the unsatisfactory reproducibility 
of the WHO classification reported by some studies.16–18
Another conceptual change concerns the reporting of 
more than 30% of thymomas that show more than one histo-
logical pattern (Moran et al.19 find >50% on extensive sam-
pling).20 Instead of using the term “combined TETs,”1 the 
diagnosis should list all the histological thymoma types that 
are encountered, starting with the most prominent component; 
minor components should be reported subsequently and quan-
tified in 10% increments.5 This rule is not applicable to type 
AB thymoma (a distinct thymoma entity) and tumors with a 
carcinoma component of whatever size (see “Combined thy-
mic carcinomas” below).
A third conceptual change is the introduction of immu-
nohistochemical features as criteria for diagnosis of thymo-
mas with ambiguous histology. Examples are the distinction 
of type A and AB thymomas by the paucity versus abundance 
of immature TdT+ T cells, or the different patterns of coarse 
versus delicate cytokeratin networks in type AB and B1 thy-
momas (see below). Routine immunohistochemical markers 
that are recommended in otherwise difficult-to-classify thy-
momas and thymic carcinomas are given in Table 3.3
A final conceptual change concerns the appreciation 
that all major thymoma subtypes can behave in a clinically 
aggressive fashion19 and therefore should no longer be called 
benign tumors, irrespective of tumor stage. Accordingly, their 
ICD-O codes now have a /3 suffix, labeling them as malignant 
(Table 1). Exceptions are micronodular and microscopic thy-
momas, for which fatal outcomes are not on record. 
Key new discoveries
Improved genetic,21–23 epigenetic,24,25 and transcrip-
tomic23,26 analyses have augmented our knowledge about the 
distinct molecular basis of thymomas and thymic carcinomas. 
The latter show mutations of epigenetic regulatory genes,21 
methylation patterns,25 and expression profiles of antiapoptotic 
genes26 that clearly distinguish them from thymomas. On the 
other hand, the identification of a highly recurrent point muta-
tion in the GTF2I oncogene in all major thymoma subtypes 
and thymic carcinomas22 is a seminal finding that underlines 
the unique tumor biology of TETs and lends strong support to 
the WHO-based subtyping of thymic tumors.27 Nevertheless, 
new predictive markers with therapeutic perspective are still 
awaited.28,29
Individual changes concerning thymoma subtypes
Atypical type A thymoma: A new addition in the 4th edi-
tion is the delineation of an “atypical type A thymoma vari-
ant” from conventional type A thymomas (Table 1). The 
new term reflects the experience that rare type A thymomas 
can show hypercellularity, increased mitotic activity, and 
TABLE 2.  Refinement of Diagnostic Criteria of Thymomas in the 2015 WHO Classification of Thymic Tumors3 by Stressing 
Obligatory and Optional Features
Thymoma Subtype Obligatory Criteria Optional Criteria
Type A Occurrence of bland, spindle-shaped epithelial cells (at least focally);  
paucitya or absence of immature (TdT+) T cells throughout the tumor
Polygonal epithelial cells; CD20+ epithelial cells
Atypical type A 
variant
Criteria of type A thymoma; in addition, comedo-type tumor necrosis; increased 
mitotic count (>4/2 mm2); nuclear crowding
Polygonal epithelial cells; CD20+ epithelial cells
Type AB Occurrence of bland, spindle-shaped epithelial cells (at least focally); abundancea 
of immature (TdT+) T cells focally or throughout tumor
Polygonal epithelial cells; CD20+ epithelial cells
Type B1 Thymus-like architecture and cytology: abundance of immature T cells, areas of 
medullary differentiation (medullary islands); paucity of polygonal or dendritic 
epithelia cells without clustering (i.e., <3 contiguous epithelial cells)
Hassall’s corpuscles; perivascular spaces
Type B2 Increased numbers of single or clustered polygonal or dendritic epithelial cells 
intermingled with abundant immature T cells
Medullary islands; Hassall’s corpuscles; 
perivascular spaces
Type B3 Sheets of polygonal slightly to moderately atypical epithelial cells; absent or rare 
intercellular bridges; paucity or absence of intermingled TdT+ T cells
Hassall’s corpuscles; perivascular spaces
MNTb Nodules of bland spindle or oval epithelial cells surrounded by an epithelial cell-
free lymphoid stroma
Lymphoid follicles; monoclonal B cells and/or 
plasma cells (rare)
Metaplastic 
thymoma
Biphasic tumor composed of solid areas of epithelial cells in a background of 
bland-looking spindle cells; absence of immature T cells
Pleomorphism of epithelial cells; actin, keratin, or 
EMA- 
positive spindle cells
Rare othersb
The atypical type A thymoma variant (in bold) is the only new addition to the “historic” list of thymoma subtypes.1
aPaucity versus abundance: any area of crowded immature T cells or moderate numbers of immature T cells in more than 10% of the investigated tumor are indicative of 
“abundance.”
bMicroscopic thymoma, sclerosing thymoma, lipofibroadenoma.
WHO, World Health Organization; MNT, micronodular thymoma with lymphoid stroma.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1387Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 10, October 2015 2015 WHO Classification of Tumors of the Thymus
necrosis (Fig. 3). Necrosis in particular appears to correlate 
with advanced stage, including metastasis.5,30–32 Rare type AB 
thymomas can show similar features.30 The clinical signifi-
cance of this variant needs further studies.
Type A versus AB thymoma: The distinction between type 
A and AB thymoma has been notoriously difficult.16–18 It is 
now stressed that both thymoma types share the occurrence 
of bland-looking spindle epithelial cells (that may optionally 
TABLE 3.  Markers Considered to Be Useful for the Routine Immunohistochemical Characterization of Otherwise  
Difficult-to-Classify Thymomas and Thymic Carcinomas3
Marker Cellular and Subcellular Targets of Mediastinal Tumors
Cytokeratins Epithelial cells of normal thymus, thymomas,a thymic carcinomas, neuroendocrine tumors, many germ cell tumors, rare sarcomas, and 
dendritic cell tumors; metastases to the mediastinum
Cytokeratin 19 Epithelial cells of normal thymus, thymomas,a and thymic carcinomas
Cytokeratin 20 Negative in normal thymus and thymomas. May be positive in rare thymic adenocarcinomas, teratomas, or metastases
P63 Nuclei of normal and neoplastic thymic epithelial cells, squamous epithelial cells (e.g., in teratoma, metastasis), primary mediastinal large 
B-cell lymphoma
P40 Nuclei of normal and neoplastic thymic epithelial cells, squamous epithelial cells (e.g., in teratoma, metastasis)
TdT Immature T cells of normal thymus, >90% of thymomas, and neoplastic T cells of T lymphoblastic lymphoma
CD5 Immature and mature T cells of thymus and >90% of thymomas, neoplastic T cells of many T lymphoblastic lymphomas; epithelial cells 
in 70% of thymic carcinomasb
CD20 Normal and neoplastic B cells, epithelial cells in 50% of cases of type A and AB thymoma
CD117 Epithelial cells in 80% of thymic carcinomas, neoplastic cells in most seminomas
aBeware of rare cytokeratin-negative thymomas (that typically maintain expression of p63/p40).82
bBeware of adenocarcinoma metastases to the mediastinum that can be CD5+ as well.
FIGURE 3.  Conventional type A thymoma versus atypical type A thymoma variant. A, Conventional type A thymoma exhibit-
ing areas composed of spindle cells (upper half) and polygonal cells (lower half) separated by a broad fibrous septum. B and C. 
Atypical type A thymoma variant showing various degrees of spontaneous necrosis in polygonal cell areas. This tumor invaded 
the lung and showed a missense mutation (chromosome 7 c.74146970T>A) in the GTF2I gene that is common in type A 
 thymomas but rare in type B thymomas and thymic carcinomas.22
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be accompanied by oval or polygonal tumor cells) and are 
distinguished from each other by a low and high content of 
immature T cells, respectively (Fig. 4A–C). Any lymphocyte-
dense areas (with crowded TdT+ cells that are “impossible to 
count” in “type B-like” areas) or more than 10% tumor areas 
with a moderate infiltrate of immature T cells should prompt 
classification as type AB thymoma.5 The close relationship 
between type A and AB thymomas is strongly supported by 
largely overlapping genetic alterations.22 However, it will be 
interesting to study whether this genetic overlap applies to 
lymphocyte-poor and lymphocyte-rich areas in type AB thy-
moma alike.
Type B thymomas and distinction from thymic carcinoma: 
Type B1 and B2 thymomas are, by definition, both lymphocyte-
rich tumors. To improve their distinction from one another, 
which can be difficult,17,18 the thymus-like architecture and 
cytology of B1 thymomas are highlighted as obligatory criteria, 
including presence of medullary islands as a “must” and absence 
of epithelial cell clusters. By contrast, type B2 thymomas must 
show a higher than normal number of polygonal (nonspindle) 
neoplastic epithelial cells that usually occur in clusters (defined 
as three or more contiguous epithelial cells). Medullary islands 
optionally occur in type B2 thymomas, whereas Hassall’s cor-
puscles occur as optional feature usually in type B1 and rarely 
in B2 thymomas (Table 2). Cytokeratin (and p40/p63) expres-
sion patterns may be helpful to distinguish type B1 from type 
B2 (and AB) thymoma (Fig. 5).
Type B3 thymoma is a lymphocyte-poor, epithelial-rich 
tumor but distinction from type B2 thymomas may be diffi-
cult.5 Because of the lack of distinguishing markers, the dif-
ferential diagnosis rests on the visual impression that type B2 
thymomas look blue on HE staining (because of the presence 
of many admixed lymphocytes), whereas type B3 thymomas 
look pink (because of sheets of confluent tumor cells).
The distinction of type B3 thymoma from thymic squa-
mous cell carcinoma (TSQCC) can be a challenge when rare 
tumors with a type B3 thymoma morphology show focal 
expression of “TSQCC-markers” (such as CD5 and CD117) 
and/or lack of “type B3 thymoma markers” (such as TdT+ 
T cells), or when tumors with a TSQCC morphology harbor 
(usually rare) TdT+ immature T cells.5 In the 4th edition, it is 
now stated that tumors that look like type B3 thymoma on HE 
staining should be diagnosed as type B3 thymoma, and tumors 
with TSQCC morphology should be labeled as TSQCC, irre-
spective of immunohistochemistry.
Other thymomas: No major changes have been introduced. In 
metaplastic thymomas, exclusive staining of the polygonal but 
not the spindle cell component for p63 or p40 may be diag-
nostically helpful.
Thymic Carcinomas Including 
Combined Thymic Carcinomas
Conceptual continuity
With few exceptions [e.g., nuclear protein in testis 
(NUT) carcinomas, adenocarcinomas], the nomenclature and 
diagnostic criteria of almost all thymic carcinoma subtypes 
remain unchanged. The Masaoka–Koga staging system may 
still be used for thymic carcinomas till publication of the new 
UICC/AJCC–approved TNM system (supposedly in 2016).
Conceptual changes
The thymic adenocarcinomas are gathered in one 
chapter and labeled according to their HE histology, aban-
doning the distinction between papillary and nonpapillary 
adenocarcinomas.
Although the term “combined TETs” was abandoned 
in the 4th edition (see above), the term Combined thymic car-
cinomas was introduced for tumors that are either composed 
FIGURE 4.  Immunohistochemistry: an important tool for the diagnosis of difficult-to-classify type A versus AB thymomas. A, 
Abundance of TdT+ immature T cells in type AB thymoma; any such crowding of TdT+ T cells excludes the diagnosis of type 
A thymoma. B, Moderate numbers of TdT+ immature T cells in a spindle cell thymoma imply a diagnosis of type AB thymoma 
when occurring in more than 10% of the tumor, if occurring in less than or equal to 10% of the tumor, a diagnosis of type A 
thymoma should be rendered. C, Near absence of TdT+ immature T cells in type A thymoma.
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of different types of thymic carcinomas (extremely rare) or 
of a thymic carcinoma and any type of thymoma or carci-
noid (rare). However, in analogy to the lung, heterogeneous 
TETs with a small-cell carcinoma (SCC) component or a 
large-cell neuroendocrine carcinoma (LCNEC) component 
are not counted among the combined thymic carcinomas 
but among the neuroendocrine carcinomas (see below). 
The reporting of a combined thymic carcinoma must start 
with the carcinoma component irrespective of its propor-
tion, followed by the thymoma component.5 In case of two 
or more carcinoma components, the dominant component is 
reported first.
Changes concerning individual 
thymic carcinoma subtypes
Thymic squamous cell carcinomas: FoxN1 and CD205 are 
novel markers31 that complement CD5 and CD117 as markers 
that are expressed in most TSQCC but not in pulmonary squa-
mous cell carcinomas. In 10% to 20% of mediastinal squamous 
cell carcinomas without expression of these markers, staging 
remains paramount to distinguish thymic from pulmonary pri-
maries. Among the many new molecular findings in thymic 
carcinoma (reviewed by Rajan et al.27)  significant predictive 
markers remain to be identified.
Basaloid carcinoma of the thymus: In the lung, carcinomas 
with basaloid features, including prominent palisading as 
hallmark, are termed “basaloid squamous cell carcinoma” and 
considered a high-grade variant of squamous cell carcinoma 
with distinct genetic features.33 In the thymus, cancers with 
basaloid features show a more varied histology (including a 
wide range of proliferative activities, common macropapillary 
growth pattern, and association with cysts) and a broader spec-
trum of clinical aggressiveness.34 Genetic data are sparse and 
not overlapping with those of pulmonary basaloid squamous 
cell carcinoma.35 Therefore, the term “basaloid carcinoma of 
the thymus” is maintained in the 4th edition (Table 1).
Mucoepidermoid carcinoma: Translocation of the MAML2 
gene is characteristic of almost all low-grade mucoepider-
moid carcinomas (MECs) and many high-grade MECs of 
salivary glands,36 bronchi, and lung.37 This translocation has 
recently been observed in thymic MECs as well,38 allow-
ing their distinction from adenosquamous carcinomas and 
adenocarcinomas.
FIGURE 5.  Immunohistochemical staining of keratin across the spectrum of type A to B3 thymomas. Of note, among the 
lymphocyte-rich thymomas a dense epithelial cell networks is typical of type AB and type B2 thymoma, whereas a delicate net-
work is an obligatory feature of type B1 thymoma.
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Sarcomatoid carcinoma: The microscopic description of sar-
comatoid carcinoma has been refined and now distinguishes 
(1) spindle cell carcinoma (malignant transformation of type 
A thymoma); (2) sarcomatoid transformation of preexisting 
thymic carcinoma; and (3) true carcinosarcoma with hetero-
logous component(s).
Adenocarcinomas: Papillary adenocarcinomas of the thymus 
usually co-occur with type A and AB thymomas and are now 
defined as low-grade carcinomas, while high-grade adeno-
carcinomas with (usually focal) papillary growth are counted 
among the “adenocarcinomas, not otherwise specified.”
Thymic carcinomas that were called “adenoid cystic 
carcinomas (ACC)” in the 3rd edition are now labeled as 
“thymic carcinomas with ACC-like features” in the 4th edi-
tion because they lack the immunohistochemical features of 
true ACC in other organs.39 Enteric differentiation (as shown 
by immunohistochemistry) occurs in a subset of mucinous 
carcinomas and adenocarcinomas, NOS, and is currently of 
unknown clinical significance. Such cases require clinical 
staging to exclude metastasis from a colorectal primary.40
NUT carcinoma: These highly aggressive cancers that were 
first observed as midline thoracic tumors in children and young 
adults and harbored a unique t(15;19)-translocation with gener-
ation of a BRD4–NUT fusion oncogene were called “carcinoma 
with t(15;19) translocation” in the 3rd edition. These tumors 
are now known to occur at all ages, outside the thorax (and 
rarely outside the midline) in approximately 40% and to show 
variant NUT translocations in approximately 30% of cases.41,42 
Therefore, these tumors are now labeled NUT carcinomas 
irrespective of anatomical location. Analysis for NUT overex-
pression by immunohistochemistry is now possible and highly 
sensitive and should be considered in any undifferentiated can-
cer, particularly if there is focal squamous differentiation.
Undifferentiated carcinoma: This tumor shows epithelial dif-
ferentiation but is otherwise a diagnosis of exclusion. Poorly 
differentiated squamous cell carcinoma, lymphoepithelioma-
like carcinoma, sarcomatoid carcinoma, NUT carcinoma, 
SCC and LCNEC, and adenocarcinoma of the thymus, GCT, 
extension from the lung and metastasis must be excluded. By 
definition, immunohistochemical markers (e.g., CK5/6, p63, 
CD5) of any of the aforementioned tumors are absent, but 
CD117 and PAX8 may be expressed.
Clinical relevance of refined thymoma 
and thymic carcinoma diagnosis
The first step when assessing a mediastinal mass is to 
establish a differential diagnosis between TETs, lymphomas, 
and other neoplasms, including metastasis. This relies on clin-
ical presentation, including neurological examination, tumor 
marker profiles, and imaging features.43 In thymic epithelial 
lesions, next steps are the differentiation of thymic malignancy 
from hyperplasia or noninvoluted thymus and the assessment 
of upfront resectability of the tumor, as complete resection 
is the most significant prognostic variable. In a postopera-
tive setting, precise histopathological subtyping is of major 
importance for treatment decisions. In this setting, postopera-
tive radiotherapy may be considered after complete resection 
of stage II thymomas with more aggressive histology, includ-
ing B2 and B3 subtypes. Chemoradiotherapy is a major com-
ponent of the therapeutic strategy of thymic carcinomas, as 
perioperative or exclusive treatment modality.44 In advanced 
stage refractory disease, KIT mutations have exclusively been 
reported to occur in thymic carcinomas, but their potential 
role as biomarkers needs further studies; meanwhile, target-
ing angiogenesis using multikinase inhibitors is of higher 
relevance in carcinomas irrespective of their KIT mutational 
status.45 By contrast, the histone deacetylase inhibitor, belino-
stat,46 the insulin-like growth factor 1 receptor-targeting anti-
body, cixutumumab,47 and somatostatin analogues48 are more 
effective in thymomas. The importance of diagnosing NUT 
carcinoma results from the ineffectiveness of conventional 
chemotherapeutic regimens and availability of promising new 
targeted agents.49
Thymic Neuroendocrine Tumors
Conceptual continuity
These chapters cover neuroendocrine epithelial tumors 
(NETs), but not paraganglioma and neurogenic tumors. In the 
4th edition, the nomenclature and criteria (Table 4) of thy-
mic typical and atypical carcinoids, LCNEC, and SCC remain 
the same as in the 3rd edition.1 The definition of “neuroen-
docrine differentiation” in the carcinoids and LCNECs, i.e., 
strong and diffuse expression of usually more than one of the 
four neuroendocrine markers (chromogranin A, synaptophy-
sin, CD56, and neuron-specific enolase) in more than 50% of 
tumor cells, has been maintained. As before, SCC remains a 
histological diagnosis; expression of neuroendocrine markers 
is often present but not required.
Conceptual changes
The descriptive terms “well-differentiated neuroendo-
crine carcinoma” (referring to carcinoids) and “poorly differ-
entiated neuroendocrine carcinoma” (referring to LCNEC and 
SCC) of the 3rd edition were abandoned, because LCNECs 
and even SCC may be highly differentiated in terms of neu-
roendocrine features. Following the strategy in the lung, the 
TABLE 4.  Thymic Neuroendocrine Tumors Covered by 
the 4th Edition of the WHO Classification of Tumours of the 
Lung, Pleura, Thymus and Heart3
Distinguishing Histological Criteria
Typical carcinoid <2 mitoses/2 mm2; no necrosis
Atypical carcinoid <2 mitoses/2 mm2; with necrosis; or
2–10 mitoses/2 mm2; + or − necrosis
LCNEC >10 mitoses/2 mm2; no small-cell features
Combined LCNEC LCNEC combined with any thymoma(s) or 
thymic carcinoma(s)
SCC Typical SCC histology
Combined SCC SCC combined with any thymoma(s) or thymic 
carcinoma(s)
Conceptual changes are in bold (these tumors were counted among the combined 
thymic epithelial tumors in the 3rd edition).
SCC, small-cell carcinoma; LCNEC, large-cell neuroendocrine carcinoma; WHO, 
World Health Organization.
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4th edition instead separates typical and atypical carcinoids 
as low-grade and intermediate-grade neuroendocrine tumors, 
respectively, from high-grade neuroendocrine carcinomas that 
comprise LCNEC and SCC.
Key new findings
A major advance has been the elucidation of genetic 
alterations at the comparative genomic hybridization level 
by an international consortium.50 The progressive increase 
and overlap of genetic gains and losses from typical car-
cinoids through atypical carcinoids to LCNECs and SCCs 
lend support to the WHO classification. Genetic alterations 
in thymic and pulmonary carcinoids are significantly dif-
ferent from each other, whereas the genetics of high-grade 
neuroendocrine tumors from thymus and lung are indistin-
guishable.50 It is the currently favored concept that different 
molecular pathways lead to thymic carcinoids and thy-
mic high-grade neuroendocrine carcinomas.50 The recent 
description of shared genetic alterations in thymic carci-
noids and associated synchronous or metachronous high-
grade neuroendocrine carcinomas challenge this view51 
and suggest that transformation of carcinoids might be an 
alternative pathway leading to high-grade neuroendocrine 
carcinomas.51,52 There are currently no immunohistological 
markers that can unequivocally distinguish between thymic 
and pulmonary primaries, although a TTF1−/PAX8 (poly-
clonal)+ profile appears to be more common in thymic car-
cinoids.53 Clinical and radiological correlation remains the 
mainstay for the distinction between thymic and pulmonary 
neuroendocrine tumors.
Individual changes in subtypes of thymic NETs
Except for new genetic data, there are no further changes 
in individual thymic NETs.
GCTs of the Mediastinum, Including 
GCTs with Somatic-Type Malignancy
Conceptual continuity
The nomenclature and histological criteria defining the 
main mediastinal GCT categories are maintained in the 4th 
edition of the WHO Classification with one minor excep-
tion: GCT with somatic-type malignancy that is a clonally 
related sarcoma, carcinoma, or both is now called “GCT with 
somatic-type solid malignancy” to stress the distinction from 
GCT with associated clonally related hematological malig-
nancies. GCTs with the latter variant of somatic-type malig-
nancy are unique to the mediastinum and called “GCTs with 
associated hematological malignancy” (Table 5).
Conceptual changes
There have been no conceptual changes.
Individual changes of GCT subtypes
The classic immunohistological markers (keratins, pla-
cental alkaline phosphatase, CD117; CD30; alpha-fetoprotein; 
β-subunit of human chorionic gonadotropin) are usually suffi-
cient to recognize even complex GCTs. Several new markers, 
such as OCT4, glypican 3, and SOX2 (Table 5), may help to 
more precisely delineate the individual components.54–56
Lymphomas of the Mediastinum
Conceptual continuity, no conceptual changes
The “new” classification of mediastinal lymphomas 
was streamlined according to the 4th edition of the WHO 
Classification of Tumours of the Haematopoietic and Lymphoid 
Tissues.10 There have been no conceptual changes (Table 1).
Individual changes of lymphoma subtypes
Primary mediastinal large B-cell lymphomas: The typical 
immunophenotype of primary mediastinal large B-cell lympho-
mas (PMBL) as reported in the 3rd edition1 (CD20+ CD79a+ 
PAX5+ CD30+/− CD15− CD10− IRF4/MUM1+/− HLADR−) 
has been complemented, among others, by CD23 (positive in 
70%) and p63 (positive in >90%), whereas p40 is absent.57 As a 
caveat, p63 is also expressed in normal and neoplastic thymic epi-
thelial cells,58 although it is typically accompanied by p40 expres-
sion.59 Despite a characteristic immunohistochemical profile, and 
a gene expression profile that extensively overlaps with that of 
Hodgkin lymphoma (HL) but not other B-cell lymphomas,60 the 
diagnosis of PMBL in daily practice still requires clinical data 
(particularly absence of extensive extrathoracic lymph node infil-
tration) to exclude systemic diffuse large B-cell lymphoma with 
mediastinal involvement.
Among the novel genetic alterations reported since 
2004, the following are of special interest from a biological 
and potentially immunotherapeutic perspective: translocations 
of the HLA class II transactivator CIITA at 16p13.13 associ-
ated with downregulation of human leukocyte antigen class II 
molecules and the almost specific amplification and/or trans-
location of the 9p24.1 region including the loci coding for 
the immune checkpoint molecules PD-L1 and programmed 
death-ligand-2 (PD-L2),61,62 which are overexpressed and 
helpful immunohistochemical markers in PMBL.63
MALT lymphoma: New genetic findings include a high fre-
quency of trisomy 3, low incidence of trisomy 18, and no 
translocations involving MALT1 and IGH.64,65
TABLE 5.  Germ Cell Tumors Covered by the 4th Edition 
of the WHO Classification of Tumours of the Lung, Pleura, 
Thymus and Heart3 and Useful Immunohistological Markers 
That Were not Mentioned in the 3rd Edition
OCT4 SALL4 Glypican 3 SOX2 SOX17
Seminoma + + − − +
Embryonal carcinoma + + − + −
Yolk sac tumor − + + − −
Choriocarcinoma + +a +b − −
Mature teratoma − −/+ +/− − −
Immature teratoma − −/+ +/− − −
Mixed GCTs
GCTs with associated somatic-type solid malignancy
GCTs with associated hematological malignancy
In bold is the new addendum “solid” to the name of GCTs that are composed of a 
GCT component and associated sarcoma and/or carcinoma.
aMononuclear trophoblast.
bSyncytiotrophoblast.
GCT, germ cell tumors; WHO, World Health Organization.
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T lymphoblastic leukemia/lymphoma: The new edition high-
lights a subset of TdT-negative cases.66 The latter might be 
related to early thymic progenitor T-ALLs that coexpress early 
myeloid markers and stem cell markers (CD34 and CD117). 
These are considered high-risk subgroups.67,68
Among many novel genetic alterations detected, muta-
tions of NOTCH1/FXBW are associated with a favorable out-
come,69 whereas loss of heterozygosity at 6q has a negative 
impact on prognosis.70
Anaplastic large-cell lymphoma: In contrast to the 3rd edi-
tion, the 4th edition (like the WHO book on hematological 
malignancies10) emphasizes the difference between anaplastic 
lymphoma kinase (ALK)(+) and ALK(−) anaplastic large-
cell lymphoma (ALCL). Both arise only exceptionally in 
the mediastinum. By immunohistochemistry, ALCL must 
be distinguished from other CD30-positive lymphomas and 
epithelial membrane antigen-positive solid tumors, includ-
ing carcinomas, and from melanomas. However, the diagno-
sis of ALK(−) ALCL versus CD30-positive peripheral T cell 
lymphoma, NOS, still rests on the identification of “hallmark 
cells” in a background of large-cell lymphoma, but the dis-
tinction may sometimes be arbitrary.
Hodgkin lymphoma: The diagnostic criteria of HL [virtually 
all mediastinal cases are nodular sclerosis classical HL (cHL)] 
have remained unchanged. A number of inactivating muta-
tions, amplifications, and translocations have been described 
that affect nuclear factor kappa-light-chain-enhancer of acti-
vated B cells, Janus kinase and signal transucer and activator of 
transcription, DNA damage, and apoptosis pathways as well as 
epigenetic homeostasis (reviewed by Kuppers71). Recognition 
that genetic and transcriptomic variation of the tumor cells and 
tumor-associated T cells and macrophages have prognostic rel-
evance is also new.72–74 Nonetheless, stage remains the single 
most important prognostic factor in mediastinal HL.
B-cell lymphoma, unclassifiable, with features intermediate 
between diffuse large B-cell lymphoma and classical HL: In 
the 3rd edition, this aggressive lymphoma was included in the 
“grey zone between HL and non-Hodgkin lymphoma.” A cur-
rent synonym is “mediastinal grey zone lymphoma (MGZL).” 
Refined diagnostic criteria include a sheet-like growth pattern 
of large, pleomorphic tumor cells including Hodgkin cells, a 
less prominent inflammatory background than cHL, usually 
preserved B-cell program (expression of CD20, PAX5, OCT2, 
BOB.1; clonal immunoglobulin gene rearrangement), expres-
sion of CD30 (consistently) and CD15 (variably), and lack of 
CD10 and ALK1 expressions. There are distinctive genetic 
and epigenetic features of MGZL in addition to features that 
overlap with cHL and PMBL (Fig. 6).75–77
Clinical relevance of refined mediastinal 
lymphoma diagnosis
Accurate diagnosis is essential for the differential treat-
ment of mediastinal cHL, PMBL, and MGZL. Patients with 
cHL currently receive polychemotherapy that seems to require 
inclusion of bleomycin and dacarbazin (e.g., ABVD) followed 
by involved field irradiation for optimal outcome.78 PMBL, 
despite its close molecular relationship to cHL, has been treated 
very differently, e.g., with CHOP and rituximab (R-CHOP) 
followed by radiotherapy. However, a recent study shows that 
radiation may be dispensable in PMBL when R-CHOP is 
replaced by the dose-adjusted etoposide, prednisone, vincris-
tine, cyclophasphamide, doxorubicin plus rituximab regimen 
(DA-EPOCH-R).79 This might be advantageous usually in the 
young female patients with PMBL because mediastinal radio-
therapy has potentially serious late effects, such as cardiovascu-
lar disease, lung cancer, and breast cancer.80 For patients with 
MGZL, DA-EPOCH-R treatment alone may not be sufficient 
because they more often required additional radiation to achieve 
long-term complete remission than patients with PMBL.79
RTB
CHLNS
MGZL
PMBL
DLBCL
FIGURE 6.  Distinct epigenetic profile of 
mediastinal grey zone lymphoma (MGZL) as 
assessed by principal component analysis. 
The methylation data for 1421 CpG targets 
from various lymphomas and reactive tonsil-
lar B cells (RTB) were subjected to principal 
component analysis and projected onto the 
first three principal components. MGZL has 
a distinct epigenetic profile intermediate 
between classical Hodgkin lymphoma, nod-
ular sclerosis subtype (CHLNS), and primary 
mediastinal large B-cell lymphoma (PMBL), 
but different from that of diffuse large B-cell 
lymphoma (DLBCL) and RTB. Adapted from 
Eberle et al.75 with permission.
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Histiocytic and Dendritic Cell 
Neoplasms of the Mediastinum
Conceptual continuity
The classification of mediastinal histiocytic and den-
dritic cell tumors was streamlined according to the 4th edition 
of the WHO Classification of Tumours of the Haematopoietic 
and Lymphoid Tissues.10
Conceptual changes
The only changes are (i) the deletion of the terms “fol-
licular dendritic cell (FDC) tumor” and “interdigitating dendritic 
cell (IDC) tumor” (i.e., tumors of unknown malignant poten-
tial, ICD-O codes: 9758/1 and 9757/1, respectively) because all 
FDC and IDC neoplasias are now considered malignant; (ii) the 
addition of the previously neglected “fibroblastic reticular cell 
tumors,” “indeterminate dendritic cell tumors,” and rare dendritic 
cell tumors with mixed phenotypes (hybrid dendritic cell tumors).
Individual changes of histiocytic and dendritic cell tumors:
A new finding is the detection of BRAF mutations in 
approximately 50% of all cases of Langerhans cell histiocyto-
sis, including mediastinal cases.81
In terms of differential diagnosis, the new WHO classifica-
tion of tumors of the thymus clarifies some important diagnostic 
challenges that need careful immunohistochemical analysis:
 1.  S100-positive Langerhans cell lesions, indeterminate den-
dritic cell tumors, and IDC sarcomas must be distinguished 
from the much more common metastatic melanoma, nerve 
sheath tumors, and myoepithelial lesions. CD1a+ Langerin+ 
Langerhans cell neoplasms need to be distinguished from 
CD1a+ Langerin− indeterminate dendritic cell tumors.
 2.  The EMA-positive and/or D2-40-positive subset of FDC 
sarcomas must not be confused with cytokeratin-defi-
cient thymomas,82 meningioma, and mesothelioma.
 3.  The cytokeratin-positive, actin-positive, or desmin-
positive subsets of fibroblastic reticular cell tumors need 
to be distinguished from spindle cell epithelial tumors 
(e.g., atypical type A thymomas and sarcomatoid carci-
nomas), smooth muscle and myofibroblastic tumors, and 
angiomatoid fibrous histiocytoma.
Myeloid Sarcoma and Extramedullary Leukemia
There have been no conceptual or individual changes.
Soft-Tissue Tumors of the Mediastinum
Conceptual continuity, no conceptual changes
The classification of mediastinal soft-tissue tumors 
was streamlined according to the 4th edition of the WHO 
Classification of Tumours of Soft Tissue and Bone.11 There 
have been no conceptual changes since the 3rd edition of the 
WHO book (Table 1). 
Individual changes in subtypes of soft-tissue tumors
Diagnostic criteria of all entities are maintained. New, 
diagnostically useful genetic alterations when compared with 
the 3rd edition are STAT6 translocation in solitary fibrous 
tumors83 and MYC gene amplification in radiation-induced 
(angio-) sarcomas.84,85
In contrast to the WHO Classification of Tumours of 
Soft Tissue and Bone,11 the 3rd and 4th editions of the WHO 
Classification of Tumours of the Lung, Pleura, Thymus and Heart 
cover neurogenic tumors that are among the most common tumors 
in the posterior mediastinum. The exceedingly rare neuroblasto-
mas and ganglioneuroblastomas of the thymic region are unusual 
because they occur in elderly patients.86,87 It is unknown, whether 
they are genetically distinct from their childhood counterparts.
Ectopic Tumors of the Thymus and 
Metastasis to the Thymus
There have been no conceptual or individual changes.
PERSPECTIVES AND CHALLENGES
The molecular revolution has just begun to approach 
TETs,22,24 but the understanding of their biology is far away 
from the level reached in many hematological and solid 
tumors. However, The Cancer Genome Atlas has recently 
included TETs for analysis of genetic, transcriptomic, and epi-
genetic changes in relation to clinicopathologic and follow-
up data. Exploiting the databases compiled by the ITMIG6–9 
might further promote our understanding of TETs and open 
perspectives for targeted therapies. In addition to this bench-
to-bedside perspective, new clues to the molecular and cellular 
pathogenesis of thymic tumors can also be expected through 
clinical trials22 that segregate patients into responders and non-
responders and thus open new avenues for bedside-to-bench 
studies of unknown underlying molecular mechanisms.29
An intriguing new molecular finding that may give a 
first hint to the etiology of TETs is the recent description of 
human polyomavirus 7 in the epithelial cells of the majority of 
TETs and of some hyperplastic thymuses of adults but not of 
fetal thymic tissue.88 If confirmed, this might have an impact 
on the classification of TETs and their clinical management.
Finally, a new staging system for thymomas and thymic 
carcinomas is on the horizon15 but awaits approval by UICC 
and AJCC.
Taken together, the 4th edition of the WHO Classification 
of thymic tumors has added important new data to the pre-
vious edition but can be expected to require amendments or 
additions because of significant new discoveries before long.
What are the challenges that need to be tackled in the 
years ahead to translate a foreseeable better understanding of 
thymoma and thymic carcinoma biology into improved man-
agement of patients? A so far unresolved key problem that has 
strongly inhibited functional in vitro and preclinical in vivo stud-
ies is the paucity of permanent bona fide thymoma and thymic 
carcinoma cell lines26,89,90 and the virtual absence of relevant 
spontaneous and xenograft-based animal models.91 Except for 
the rarity of thymomas and thymic carcinomas, the lack of cell 
lines and functional xenografts is likely because of the essen-
tial need of neoplastic thymic epithelial cells for crosstalk with 
stromal cells and particularly developing T cells in the case of 
thymomas to prevent senescence in vitro.26 Therefore, systems 
biology approaches will likely be necessary to decipher the com-
plex ligand-based and paracrine networks that help to sustain the 
survival of neoplastic epithelial cells in vivo and might be essen-
tial in vitro as well. This knowledge might be a prerequisite to 
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establish relevant models for preclinical functional studies and, 
ultimately, high-throughput state-of-the-art drug testing.
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